Showing all news

MRC Technology strengthens its collaborative relationships in Scandinavia

MRC Technology (MRCT) and the University of Turku (UTU, Finland) have signed a memorandum of understanding outlining how they will work together to translate biological and medical research from UTU into new therapeutics and diagnostics. UTU researchers have considerable expertise in molecular biosciences, cardiovascular and metabolic research, with particular strengths in diagnostic development and antibody technologies. UTU’s research expertise shares synergy with MRCT’s collaborative diagnostic and therapeutic discovery programmes, which help progress early-stage academic projects towards the clinic. Through this agreement, MRCT and UTU aim to combine their capabilities to move promising medical research forward into viable and accessible diagnostics and patient treatments.

21 October 2015

EU Consortium receives funding for detection and prevention of diseases associated with ageing

Marie Skłodowska-Curie actions has awarded €2,887,054.24 to an EU consortium, including MRC Technology, to provide training for 11 young researchers in innovative therapeutic strategies. EVOluTION, the European Vascular Interventions and Therapeutic Innovation Network, aims to find novel approaches to manage chronic vascular and metabolic diseases affecting the increasing ageing population, focusing on early detection and prevention.

MRC Technology will receive €273,287.88 and the project starts 1 April 2016.

Further information

17 September 2015

Dementia Consortium funds project focusing on ALS and FTLD

A project to identify new agents capable of stimulating clearance of a protein that forms aggregates in neurons of patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Lobar degeneration (FTLD) has received funding worth £305,000 from the Dementia Consortium.

14 September 2015

Georg-August-University Göttingen, Universitätsmedizin and MRC Technology collaborate to develop new therapy for neurodegenerative diseases

Georg-August-University Göttingen (UMG) and MRC Technology (MRCT) have signed a collaboration agreement for the development of a novel therapy for neurodegenerative diseases based on an antibody that targets particular forms of amyloid beta peptides, amyloid beta 4-x. The aim is to develop a new antibody therapy for Alzheimer’s Disease (AD).

28 July 2015

Keytruda: A first-in-class cancer therapy

BIA’s report, Celebrating UK bioscience, features UK bioscience successes. It incldes Keytruda, a new generation drug which uses the body’s immune system to fight cancer. It features MRC Technology’s role humanising the antibody. Read the article.  

27 July 2015
Showing all news